Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Archives of Gynecology and Obstetrics
Published in: Archives of Gynecology and Obstetrics 3/2014

01-03-2014 | Maternal-Fetal Medicine

Medical prevention and treatment of postpartum hemorrhage: a comparison of different guidelines

Authors: Michael K. Bohlmann, Werner Rath

Published in: Archives of Gynecology and Obstetrics | Issue 3/2014

Login to get access

Abstract

Background

Postpartum hemorrhage (PPH) remains a common cause of maternal mortality worldwide, mainly caused by uterine atony. Medical intervention plays an important part in prevention and therapies of PPH. Prophylactic interventions include the use of uterotonic drugs. We elaborated the consistency of national and international guidelines on those medical approaches.

Materials and methods

Medical approaches in PPH were extracted from recent publications. Furthermore, the current guidelines of the World Health Organization, the FIGO and of the American, British, Canadian and German Societies of Obstetricians and Gynecologists on PPH were analyzed.

Results

Oxytocin is considered as therapy of first choice. However, the examined guidelines fail to give unequivocal recommendations on further uterotonics in PPH, which may partially be attributed to differing publication dates of the guidelines.

Conclusion

International guidelines on PPH are characterized by differing recommendations. However, recent publications suggest that adhering to local guidelines significantly reduces the prevalence of severe PPH.
Literature
1.
Abou Zahr C (2003) Global burden of maternal death and disability. Br Med Bull 67:1–11CrossRef
2.
ACOG Practice Bulletin (2006) Clinical management guidelines for obstetricians and gynecologists: postpartum hemorrhage. Number 76. Obstet Gynecol 108:1039–1047CrossRef
3.
Aeby A, Johansson AB, De Schuiteneer B, Blum D (2003) Methylergometrine poisoning in children: review of 34 cases. J Toxicol Clin Toxicol 41:249–253PubMedCrossRef
4.
5.
Askar AA, Ismail MT, El-Ezz AA, Rabie NH (2011) Carbetocin versus syntometrine in the management of third stage of labor following vaginal delivery. Arch Gynecol Obstet 284:1359–1365PubMedCrossRef
6.
Badejoko OO, Ijarotimi AO, Awowole IO, Loto OM, Badejoko BO, Olaiya DS et al (2012) Adjunctive rectal misoprostol versus oxytocin infusion for prevention of postpartum hemorrhage in women at risk: a randomized controlled trial. J Obstet Gynaecol Res 38:1294–1301PubMedCrossRef
7.
Begley CM, Gyte GM, Devane D, McGuire W, Weeks A (2011) Active versus expectant management for women in the third stage of labour. Cochrane Database Syst Rev 11:CD007412PubMed
8.
Bellad MB, Tara D, Ganachari MS, Mallapur MD, Goudar SS, Kodkany BS, Sloan NL, Derman R (2012) Prevention of postpartum haemorrhage with sublingual misoprostol or oxytocin: a double-blind randomised controlled trial. BJOG 119:975–982PubMedCrossRef
9.
Biswas A, Roy S (1996) A comparative study of the efficacy and safety of synthetic prostaglandin E2 derivative and 15-methyl prostaglandin F2 alpha in the termination of midtrimester pregnancy. J Indian Med Assoc 94:292–293PubMed
10.
Bolton TJ, Randall K, Yentis SM (2003) Effect of the confidential enquiries into maternal deaths on the use of Syntocinon® of caesarean section in the UK. Anaesthesia 58:277–279PubMedCrossRef
11.
Butwick AJ, Coleman L, Cohen SE, Riley ET, Carvalho B (2010) Minimum effective bolus dose of oxytocin during elective Caesarean delivery. Br J Anaesth 104:338–343PubMedCrossRef
12.
Carroli G, Cuesta C, Abalos E, Gülmezoglu AM (2008) Epidemiology of postpartum haemorrhage: a systematic review. Best Pract Res Clin Obstet Gynaecol 22:999–1012PubMedCrossRef
13.
Carvalho JC, Balki M, Kingdom J, Windrim R (2004) Oxytocin requirements at elective cesarean delivery: a dose-finding study. Obstet Gynecol 104:1005–1010PubMedCrossRef
14.
Cordovani D, Balki M, Farine D, Seaward G, Carvalho JC (2012) Carbetocin at elective Cesarean delivery: a randomized controlled trial to determine the effective dose. Can J Anaesth 59:751–757PubMedCrossRef
15.
Douglas MJ, Farquharson DF, Ross PL, Renwick JE (1989) Cardiovascular collapse following an overdose of prostaglandin F2 alpha: a case report. Can J Anaesth 36:466–469PubMedCrossRef
16.
Driessen M, Bouvier-Colle MH, Dupont C, Khoshnood B, Rudigoz RC, Deneux-Tharaux C (2011) Postpartum hemorrhage resulting from uterine atony after vaginal delivery: factors associated with severity. Obstet Gynecol 117:21–31PubMedCrossRefPubMedCentral
17.
Dupont C, Touzet S, Colin C, Deneux-Tharaux C, Rabilloud M, Clement HJ et al (2009) Incidence and management of postpartum haemorrhage following the dissemination of guidelines in a network of 16 maternity units in France. Int J Obstet Anesth 18:320–327PubMedCrossRef
18.
Dupont C, Deneux-Tharaux C, Touzet S, Colin C, Bouvier-Colle MH, Lansac J, Thevenet S, Boberie-Moyrand C, Piccin G, Fernandez MP, Rudigoz RC (2011) Clinical audit: a useful tool for reducing severe postpartum haemorrhages? Int J Qual Health Care 23:583–589PubMedCrossRefPubMedCentral
19.
Dyer RA, Butwick AJ, Carvalho B (2011) Oxytocin for labour and caesarean delivery: implications for the anaesthesiologist. Curr Opin Anaesthesiol 24:255–261PubMedCrossRef
20.
Erkkola R, Kanto J, Allonen H, Kleimola T, Mäntylä R (1978) Excretion of methylergometrine (methylergonovine) into the human breast milk. Int J Clin Pharmacol Biopharm 16:579–580PubMed
21.
Gazvani MR, Luckas MJ, Drakeley AJ, Emery SJ, Alfirevic Z, Walkinshaw SA (1998) Intraumbilical oxytocin for the management of retained placenta: a randomized controlled trial. Obstet Gynecol 91:203–207PubMedCrossRef
22.
Ge J, Liao H, Duan L, Wei Q, Zeng W (2012) Uterine packing during cesarean section in the management of intractable hemorrhage in central placenta previa. Arch Gynecol Obstet 285:285–289PubMedCrossRef
23.
24.
Ghai B, Vayjnath AM, Lal S (2006) Acute pulmonary oedema following oxytocin administration: a life threatening complication. J Indian Med Assoc 104:261–262PubMed
25.
Grönvall M, Tikkanen M, Tallberg E, Paavonen J, Stefanovic V. Use of Bakri balloon tamponade in the treatment of postpartum hemorrhage: a series of 50 cases from a tertiary teaching hospital. Acta Obstet Gynecol Scand. 2012 Aug 22. (Epub ahead of print)
26.
Gülmezoglu AM, Forna F, Villar J, Hofmeyr GJ (2007) Prostaglandins for preventing postpartum haemorrhage. Cochrane Database Syst Rev 3:CD000494PubMed
27.
Gülmezoglu AM, Lumbiganon P, Landoulsi S, Widmer M, Abdel-Aleem H, Festin M, Carroli G, Qureshi Z, Souza JP, Bergel E, Piaggio G, Goudar SS, Yeh J, Armbruster D, Singata M, Pelaez-Crisologo C, Althabe F, Sekweyama P, Hofmeyr J, Stanton ME, Derman R, Elbourne D (2012) Active management of the third stage of labour with and without controlled cord traction: a randomised, controlled, non-inferiority trial. Lancet 379:1721–1727PubMedCrossRef
28.
Güngördük K, Asicioglu O, Besimoglu B, Güngördük OC, Yildirm G, Ark C et al (2010) Using intraumbilical vein injection of oxytocin in routine practice with active management of the third stage of labor: a randomized controlled trial. Obstet Gynecol 116:619–624PubMedCrossRef
29.
Habek D, Franicević D (2007) Intraumbilical injection of uterotonics for retained placenta. Int J Gynaecol Obstet 99:105–109PubMedCrossRef
30.
Harara R, Hanafy S, Zidan MS, Alberry M (2011) Intraumbilical injection of three different uterotonics in the management of retained placenta. J Obstet Gynaecol Res 37:1203–1207PubMedCrossRef
31.
Hayashi RH, Castillo MS, Noah ML (1984) Management of severe postpartum hemorrhage with a prostaglandin F2 alpha analogue. Obstet Gynecol 63:806–808PubMed
32.
Higgins L, Mechery J, Tomlinson AJ (2011) Does carbetocin for prevention of postpartum haemorrhage at caesarean section provide clinical or financial benefit compared with oxytocin? J Obstet Gynaecol 31:732–739PubMedCrossRef
33.
Hogerzeil HV, Walker GJ (1996) Instability of (methyl)ergometrine in tropical climates: an overview. Eur J Obstet Gynecol Reprod Biol 69:25–29PubMedCrossRef
34.
Ishibashi T, Ishibashi S, Uchida T, Nakazawa K, Makita K (2011) Reversible cerebral vasoconstriction syndrome with limb myoclonus following intravenous administration of methylergometrine. J Anesth 25:405–408PubMedCrossRef
35.
36.
Jacobs MM, Arias F (1980) Intramyometrial prostaglandin F2 alpha in the treatment of severe postpartum hemorrhage. Obstet Gynecol 55:665–666PubMed
37.
Jonsson M, Hanson U, Lidell C, Nordén-Lindeberg S (2010) ST depression at caesarean section and the relation to oxytocin dose. A randomised controlled trial. BJOG 117:76–83PubMedCrossRef
38.
Kerekes L, Domokos N (1979) The effect of prostaglandin F2 alpha on third stage labor. Prostaglandins 18:161–166PubMedCrossRef
39.
Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF (2006) WHO analysis of causes of maternal death: a systematic review. Lancet 367:1066–1074PubMedCrossRef
40.
Khan MM, Gupta S, Radford P, Male DA (2002) Dose of oxytocin after caesarean section. Anaesthesia 57:723–724PubMedCrossRef
41.
Knight M, Callaghan WM, Berg C, Alexander S, Bouvier-Colle MH, Ford JB et al (2009) Trends in postpartum hemorrhage in high resource countries: a review and recommendations from the International Postpartum Hemorrhage Collaborative Group. BMC Pregnancy Childbirth 9:55–65PubMedCrossRefPubMedCentral
42.
Krumnikl JJ, Böttiger BW, Strittmatter HJ, Motsch J (2002) Complete recovery after 2 h of cardiopulmonary resuscitation following high-dose prostaglandin treatment for atonic uterine haemorrhage. Acta Anaesthesiol Scand 46:1168–1170PubMedCrossRef
43.
Langer B, Boudier E, Haberstich R, Dreyfus M (2004) Obstetrical management in the event of persistent or worsening postpartum hemorrhage despite initial measures. J Gynecol Obstet Biol Reprod (Paris) 33(8 Suppl): 4S73–4S79
44.
Leduc D, Senikas V, Lalonde AB (2010) Active management of the third stage of labour: prevention and treatment of post partum hemorrhage (SOGC Clinical Practice Guidelines NO. 235). Int J Gynecol Obstet 108:258–267
45.
Liabsuetrakul T, Choobun T, Peeyananjarassri K, Islam QM (2007) Prophylactic use of ergot alkaloids in the third stage of labour. Cochrane Database Syst Rev 2: CD005456
46.
Maier RC (1993) Control of postpartum hemorrhage with uterine packing. Am J Obstet Gynecol 169:317–321PubMedCrossRef
47.
Makkonen M, Suonio S, Saarikoski S (1995) Intraumbilical oxytocin for management of retained placenta. Int J Gynaecol Obstet 48:169–172PubMedCrossRef
48.
Meinen K, Lange R, Breinl H (1988) Intramyometrial PGF2 alpha administration in the control of severe atonic postpartum hemorrhage. Geburtshilfe Frauenheilkd 48:268–270PubMedCrossRef
49.
McDonald S, Prendiville WJ, Elbourne D (2004) Prophylactic ergometrine-oxytocin versus oxytocin for the third stage of labour. Cochrane Database Syst Rev 1:CD000201PubMed
50.
Moertl MG, Friedrich S, Kraschl J, Wadsack C, Lang U, Schlembach D (2011) Haemodynamic effects of carbetocin and oxytocin given as intravenous bolus on women undergoing caesarean delivery: a randomised trial. BJOG 118:1349–1356PubMedCrossRef
51.
Mori R, Nardin JM, Yamamoto N, Carroli G, Weeks A (2012) Umbilical vein injection for the routine management of third stage of labour. Cochrane Database Syst Rev 3:CD006176PubMed
52.
53.
Mousa HA, Alfirevic Z (2007) Treatment for primary postpartum haemorrhage. Cochrane Database Syst Rev 1:CD003249PubMed
54.
Munn MB, Owen J, Vincent R, Wakefield M, Chestnut DH, Hauth JC (2001) Comparison of two oxytocin regimens to prevent uterine atony at cesarean delivery: a randomized controlled trial. Obstet Gynecol 98:386–390PubMedCrossRef
55.
Nardin JM, Weeks A, Carroli G (2011) Umbilical vein injection for management of retained placenta. Cochrane Database Syst Rev 5:CD001337PubMed
56.
Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL (2010) How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov 9:203–214PubMed
57.
Pinder AJ, Dresner M, Calow C, Shorten GD, O’Riordan J, Johnson R (2002) Haemodynamic changes caused by Oxytocin during caesarean section under spinal anaesthesia. Int J Obstet Anesth 11:156–159PubMedCrossRef
58.
59.
Prendiville WJ, Elbourne D, McDonald S (2000) Active versus expectant management in the third stage of labour. Cochrane Database Syst Rev 3:CD000007PubMed
60.
Pursche T, Diedrich K, Banz-Jansen C (2012) Blood loss after caesarean section: depending on the management of oxytocin application? Arch Gynecol Obstet 286:633–636PubMedCrossRef
61.
Rajan PV, Wing DA (2010) Postpartum hemorrhage: evidence-based medical interventions for prevention and treatment. Clin Obstet Gynecol 53:165–181PubMedCrossRef
62.
Rath W (2009) Prevention of postpartum haemorrhage with the oxytocin analogue carbetocin. Eur J Obstet Gynecol Reprod Biol 147:15–20PubMedCrossRef
63.
Rath W (2011) Postpartum hemorrhage: update on problems of definitions and diagnosis. Acta Obstet Gynecol Scand 90:421–428PubMedCrossRef
64.
Rath W, Hackethal A, Bohlmann MK (2012) Second-line treatment of postpartum haemorrhage (PPH). Arch Gynecol Obstet 286:549–561PubMedCrossRef
65.
(2009) RCOG Green-top Guideline No. 52: prevention and management of post partum haemorrhage. London (UK)
66.
Ribbing M, Reinecke H, Breithardt G, Kerber S (2001) Acute anterior wall infarct in a 31-year-old patient after administration of methylergometrin for peripartal vaginal hemorrhage. Herz 26:489–493PubMedCrossRef
67.
Roach MK, Abramovici A, Tita AT (2012) Dose and duration of oxytocin to prevent postpartum hemorrhage: a review. Am J Perinatol Dec 3. (Epub ahead of print)
68.
Rogers MS, Yuen PM, Wong S (2007) Avoiding manual removal of placenta: evaluation of intra-umbilical injection of uterotonics using the Pipingas technique for management of adherent placenta. Acta Obstet Gynecol Scand 86:48–54PubMedCrossRef
69.
Rydén G, Sjöholm I (1969) Half-life of oxytocin in blood of pregnant and non-pregnant women. Acta Endocrinol (Copenh) 61:425–431
70.
Samangaya R, Pennington R, Vause S (2010) Factors relating to a rising incidence of major postpartum haemorrhage. BJOG 117:370–371PubMedCrossRef
71.
Sartain JB, Barry JJ, Howat PW, McCormack DI, Bryant M (2008) Intravenous oxytocin bolus of 2 units is superior to 5 units during elective Caesarean section. Br J Anaesth 101:822–826PubMedCrossRef
72.
Schmitz T, Tararbit K, Dupont C, Rudigoz RC, Bouvier-Colle MH, Deneux-Tharaux C (2011) Prostaglandin E2 analogue sulprostone for treatment of atonic postpartum hemorrhage. Obstet Gynecol 118:257–265PubMedCrossRef
73.
Sekimoto E, Kunishige M, Kuriwaka R, Shinohara M, Ebisutani D, Kitamura K et al (2002) Delayed vasospasm in late postpartum cerebral angiopathy after withdrawal of methylergometrine. Cerebrovasc Dis 13:288–289PubMedCrossRef
74.
Silcox J, Schulz P, Horbay GL, Wassenaar W (1993) Transfer of carbetocin into human breast milk. Obstet Gynecol 82:456–459PubMed
75.
Singh G, Radhakrishnan G, Guleria K (2009) Comparison of sublingual misoprostol, intravenous oxytocin, and intravenous methylergometrine in active management of the third stage of labor. Int J Gynaecol Obstet 107:130–134PubMedCrossRef
76.
Singhi S, Chookang E, Hall JS, Kalghatgi S (1985) Iatrogenic neonatal and maternal hyponatraemia following oxytocin and aqueous glucose infusion during labour. Br J Obstet Gynaecol 92:356–363PubMedCrossRef
77.
Soltani H, Hutchon DR, Poulose TA (2010) Timing of prophylactic uterotonics for the third stage of labour after vaginal birth. Cochrane Database Syst Rev 8:CD006173PubMed
78.
Stefanovic V, Paavonen J, Loukovaara M, Halmesmäki E, Ahonen J, Tikkanen M (2012) Intravenous sulprostone infusion in the treatment of retained placenta. Acta Obstet Gynecol Scand Aug 1. (Epub ahead of print)
79.
Su LL, Rauff M, Chan YH, Mohamad Suphan N, Lau TP, Biswas A et al (2009) Carbetocin versus syntometrine for the third stage of labour following vaginal delivery—a double-blind randomised controlled trial. BJOG 116:1461–1466PubMedCrossRef
80.
Su LL, Chong YS, Samuel M (2012) Carbetocin for preventing postpartum haemorrhage. Cochrane Database Syst Rev 4:CD005457PubMed
81.
Tamhane P, O’Sullivan G, Reynolds F (2006) Oxytocin in parturients with cardiac disease. Int J Obstet Anesth 15:332–333PubMedCrossRef
82.
Takeda S, Kuwabara Y, Mizuno M (1986) Concentrations and origin of oxytocin in breast milk. Endocrinol Jpn 33:821–826PubMedCrossRef
83.
Thibonnier M, Conarty DM, Preston JA, Plesnicher CL, Dweik RA, Erzurum SC (1999) Human vascular endothelial cells express oxytocin receptors. Endocrinology 140:1301–1309PubMed
84.
Thilaganathan B, Cutner A, Latimer J, Beard R (1993) Management of third-stage of labour in women with low risk of postpartum haemorrhage. Eur J Obstet Gynecol Reprod Biol 48:19–22PubMedCrossRef
85.
Thomas JS, Koh SH, Cooper GM (2007) Haemodynamic effects of oxytocin given as i.v. bolus or infusion on women undergoing Caesarean section. Br J Anaesth 98:116–119PubMedCrossRef
86.
Tsui BC, Stewart B, Fitzmaurice A, Williams R (2001) Cardiac arrest and myocardial infarction induced by postpartum intravenous ergonovine administration. Anesthesiology 94:363–364PubMedCrossRef
87.
Upadhyay K, Scholefield H (2008) Risk management and medicolegal issues related to postpartum haemorrhage. Best Pract Res Clin Obstet Gynaecol 22:1149–1169PubMedCrossRef
88.
Vankrieken L, Godart A, Thomas K (1983) Oxytocin determination by radioimmunoassay. Gynecol Obstet Invest 16:180–185PubMedCrossRef
89.
Vincenti E, Tambuscio B, Marchesoni D, Graziottin A, Di Lenardo L, Chiaranda M (1982) Use of intramyometrial injection of prostaglandin F 2 alpha in the management of intractable hemorrhage due to uterine atony. Clin Exp Obstet Gynecol 9:26–30PubMed
90.
Vogel D, Burkhardt T, Rentsch K, Schweer H, Watzer B, Zimmermann R et al (2004) Misoprostol versus methylergometrine: pharmacokinetics in human milk. Am J Obstet Gynecol 191:2168–2173PubMedCrossRef
91.
Wang JY, Lin SH, Lin YF, Chen HY, Yu FC, Fu MT (2000) An unforgotten cause of acute hyponatremia: water intoxication due to oxytocin administration in a pregnant woman. Nephron 86:342–343PubMedCrossRef
92.
Waterstone M, Bewley S, Wolfe C (2001) Incidence and predictors of severe obstetric morbidity: case-control study. BMJ 322:1089–1093PubMedCrossRef
93.
94.
WHO Guidelines for the management of post partum haemorrhage and retained placenta (2009) World Health Organisation, Geneva (Switzerland)
95.
Winter C, Macfarlane A, Deneux-Tharaux C, Zhang WH, Alexander S, Brocklehurst P, Bouvier-Colle MH, Prendiville W, Cararach V, van Roosmalen J, Berbik I, Klein M, Ayres-de-Campos D, Erkkola R, Chiechi LM, Langhoff-Roos J, Stray-Pedersen B, Troeger C (2007) Variations in policies for management of the third stage of labour and the immediate management of postpartum haemorrhage in Europe. BJOG 114:845–854PubMedCrossRefPubMedCentral
96.
Woo C, McGlennan A (2010) Minimum effective bolus dose of oxytocin during elective Caesarean delivery. Br J Anaesth 105:91–92PubMedCrossRef
97.
98.
Belghiti J, Kayem G, Dupont C, Rudigoz RC, Bouvier-Colle MH, Deneux-Tharaux C (2011) Oxytocin during labour and risk of severe postpartum haemorrhage: a population-based, cohort-nested case-control study. BMJ Open 1:e000514PubMedCrossRefPubMedCentral
99.
Endler M, Grünewald C, Saltvedt S (2012) Epidemiology of retained placenta: oxytocin as an independent risk factor. Obstet Gynecol 119:801–809PubMedCrossRef
100.
FIGO safe motherhood and newborn health (SMNH) committee (2012) Prevention and treatment of postpartum hemorrhage in low-resource settings. Int J Gynecol Obstet 117:108–118CrossRef
101.
Morlando M, Sarno L, Napolitano R, Capone A, Tessitore G, Maruotti GM, Martinelli P (2013) Placenta accreta: incidence and risk factors in an area with a particularly high rate of cesarean section. Acta Obstet Gynecol Scand 92:457–460PubMedCrossRef
102.
Potts M, Prata N, Sahin-Hodoglugil NN (2010) Maternal mortality: one death every 7 min. Lancet 375:1762–1763PubMedCrossRef
103.
Metadata
Title
Medical prevention and treatment of postpartum hemorrhage: a comparison of different guidelines
Authors
Michael K. Bohlmann
Werner Rath
Publication date
01-03-2014
Publisher
Springer Berlin Heidelberg
Published in
Archives of Gynecology and Obstetrics / Issue 3/2014
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-013-3016-4

Other articles of this Issue 3/2014

Archives of Gynecology and Obstetrics 3/2014 Go to the issue

Editorial

New associate editor: Prof. Ludwig Wildt

Gynecologic Oncology

Expression and significance of biglycan in endometrial cancer

Gynecologic Oncology

Increased osteopontin expression is associated with progression from vulvar precancerous lesions to vulvar squamous cell carcinoma

Letter to the Editor

Non-invasive management of acute recurrent puerperal uterine inversion with Bakri postpartum balloon

Gynecologic Oncology

Polymorphisms in the promoter region of estrogen receptor β gene in endometrial cancer

News and Views

Eradication of cervical cancer: the beginning of the end